Dr. David Burgess
Dr. David Burgess

Professor

Dr. David S. Burgess, a native of Mayfield, Ky, is Professor and Chair of the Department of Pharmacy Practice and Science. He earned a BS in biology and chemistry from Murray State University, a BS in Pharmacy from the University of Kentucky and his Pharm.D. from the Medical University of South Carolina. He completed a residency in Critical Care/Surgery and an Infectious Diseases Pharmacotherapy Fellowship at the Medical University of South Carolina. Prior to joining the University of Kentucky College of Pharmacy in September 2012, Dr. Burgess was at the University of Texas College of Pharmacy and University of Texas Health Science Center at San Antonio for 18 years In 2008, he was named Head of the Pharmacotherapy Division at the UT College of Pharmacy and the Director of the Pharmacotherapy Research and Education Center in the School of Medicine at the UT Health Science Center at San Antonio. Dr. Burgess has served on the Board of Directors as well as President-elect, President, and Past-President for the Society of Infectious Diseases Pharmacists. He is a Fellow of the American College of Clinical Pharmacy (FCCP) and Fellow of the American Association of Colleges of Pharmacy Academic Leadership Program. Dr. Burgess research interests lie in the area of infectious disease due to bacteria by focusing on understanding the mechanisms of resistance, pharmacokinetics, pharmacodynamics, and outcomes of antibacterial pharmacotherapy. He has provided a vast number of presentations and authored numerous scientific publications.

Interests

  • Infectious disease due to bacteria by focusing on understanding the mechanisms of resistance, pharmacokinetics, pharmacodynamics, and outcomes of antibacterial pharmacotherapy.

Recent Publications

  • Kulengowski Brandon, Burgess David S. (2017). Ceftazidime-avibactam Activity Compared to Commonly Utilized Antimicrobials against Carbapenem-resistant Enterobacteriaceae from an Academic Medical Center. ASM Microbe 2017,
  • Rutter W Cliff, Burgess David S. (2017). Acute kidney injury in patients treated with IV beta-lactam/beta-lactamase inhibitor combinations. Pharmacotherapy, 37, 593-598.
  • Crass Ryan L, Rutter W Cliff, Burgess Donna R, Martin Craig A, Burgess David S. (2017). Nephrotoxicity in Patients with and without Cystic Fibrosis Treated with Polymyxin B versus Colistimethate Sodium. Antimicrobial Agents and Chemotherapy,
  • Cliff Rutter W, Burgess Donna R, Talbert Jeffery C, Burgess David S. (2017). Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin-Tazobactam Alone and in Combination: A Retrospective Cohort Analysis. Journal of Hospital Medicine, 12, 77-82.
  • Rutter W Cliff, Cox Jessica N, Martin Craig A, Burgess Donna R, Burgess David S. (2017). Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrobial Agents and Chemotherapy, 61,
  • Rutter W Cliff, Burgess David S. (2016). Trends in Acute Injury Incidence in Patients Treated with Vancomycin plus Piperacillin-Tazobactam or Cefepime. IDWeek 2016,
  • Crass Ryan L, Rutter W Cliff, Burgess Donna R, Martin Craig A, Burgess David S, Array Array. (2016). Comparative Nephrotoxicity of Polymyxin B and Colistimethate Sodium in Patients with Cystic Fibrosis. IDWeek 2016,
  • Cady Elizabeth, Rutter W Cliff, Burgess Donna R, Kincaid Scott, Martin Craig A, Burgess David S. (2016). Utilizing Nanosphere's VerigeneĀ® Technology to Assist with Possible Rapid Pharmacologic De-escalation of Antimicrobial Therapy In A University Hospital Setting. IDWeek 2016,
  • Cotner Sarah, Rutter W Cliff, Burgess Donna R, Martin Craig A, Burgess David S, Array Array. (2016). Influence of Beta-lactam Infusion Strategy on Acute Kidney Injury. IDWeek 2016,
  • Tentant Sarah J, Burgess Donna R, Myient Thein, Burgess David S. (2016). Using Pharmacist-Driven Recommendations to Optimize Management of Staphylococcal Bacteremia . IDWeek 2016,